- Home
- ICCM
ICCM
IceCure Medical Ltd.
as 11-12-2024 4:00pm EST
Stocks
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Upcoming Earnings Alert:
Get ready for potential market movements as IceCure Medical Ltd. ICCM prepares to release earnings report on 18 Nov 2024.
| Founded: | 2006 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 29.3M | IPO Year: | N/A |
| Target Price: | $2.70 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $1.57 | Next Earning Date: | 11-18-2024 |
| Revenue: | $3,336,000 | Revenue Growth: | 3.60% |
| Revenue Growth (this year): | 18.61% | Revenue Growth (next year): | 54.91% |
Latest IceCure Medical Ltd. News
ICCM Breaking Stock News: Dive into ICCM Ticker-Specific Updates for Smart Investing
Medical Device Network
2 days ago
IceCure’s cryoablation system for breast cancer treatment gains FDA panel support
PR Newswire
5 days ago
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
PR Newswire
15 days ago
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
PR Newswire
23 days ago
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
Zacks
a month ago
Alignment HealthCare Partners With Intermountain Health in Nevada
PR Newswire
a month ago
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
Zacks
a month ago
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
PR Newswire
2 months ago
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Compare ICCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICCM IceCure Medical Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.